{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T10:34:50Z","timestamp":1769164490902,"version":"3.49.0"},"reference-count":22,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>This study aimed to develop and validate a diagnostic model for prostate cancer (PCa) by integrating magnetic resonance imaging (MRI) parameters with the immunohistochemical expression of p504s, CK5\/6, and Ki-67. A total of 448 patients undergoing prostate needle biopsy were included and randomly allocated into training (70\u202f%) and validation (30\u202f%) cohorts. Clinical data, MRI findings, and biomarker expression levels were analyzed. Multivariate logistic regression identified independent predictors, which were used to construct a diagnostic nomogram. Compared to controls, PCa patients had significantly higher PSA levels, lower f-PSA\/t-PSA ratios, a greater frequency of palpable nodules, higher CC\/C ratios, lower ADC values, increased p504s and Ki-67 positivity, and reduced CK5\/6 expression. Seven variables were ultimately identified as independent predictors for the model. The resulting nomogram demonstrated excellent discrimination, with an area under the curve (AUC) of 0.971 in the training set and 0.977 in the validation set. It significantly outperformed a model using clinical indicators alone. This combined MRI-biomarker model shows high diagnostic accuracy for PCa and could potentially aid clinical decision-making and reduce unnecessary biopsies. External validation is required prior to clinical application.<\/jats:p>","DOI":"10.1515\/biol-2025-1244","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T18:56:28Z","timestamp":1769108188000},"source":"Crossref","is-referenced-by-count":0,"title":["Development and validation of a combined diagnostic model for prostate cancer integrating MRI parameters with p504s, CK5\/6, and Ki-67 expression"],"prefix":"10.1515","volume":"21","author":[{"given":"Qingchang","family":"Ren","sequence":"first","affiliation":[{"name":"Department of Radiology , The Second People\u2019s Hospital, Wuhu , Wuhu , 241000 , Anhui , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jialong","family":"Gu","sequence":"additional","affiliation":[{"name":"Huashan Hospital Fudan University, Shanghai , 200040 , Shanghai , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nankang","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Radiology , The First Affiliated Hospital of Hainan Medical College , Haikou , 570102 , Hainan , China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2026,1,23]]},"reference":[{"key":"2026012218562268450_j_biol-2025-1244_ref_001","doi-asserted-by":"crossref","unstructured":"Achard, V, Putora, PM, Omlin, A, Zilli, T, Fischer, S. Metastatic prostate cancer: treatment options. Oncology 2022;100:48\u201359. https:\/\/doi.org\/10.1159\/000519861.","DOI":"10.1159\/000519861"},{"key":"2026012218562268450_j_biol-2025-1244_ref_002","doi-asserted-by":"crossref","unstructured":"Aina, T, Salifu, AA, Kizhakkepura, S, Danyuo, Y, Obayemi, JD, Oparah, JC, et al.. Sustained release of alpha-methylacyl-CoA racemase (AMACR) antibody-conjugated and free doxorubicin from silica nanoparticles for prostate cancer cell growth inhibition. J Biomed Mater Res B Appl Biomater 2023;111:665\u201383. https:\/\/doi.org\/10.1002\/jbm.b.35185.","DOI":"10.1002\/jbm.b.35185"},{"key":"2026012218562268450_j_biol-2025-1244_ref_003","doi-asserted-by":"crossref","unstructured":"Hugosson, J, Godtman, RA, Wallstrom, J, Axcrona, U, Bergh, A, Egevad, L, et al.. Results after four years of screening for prostate cancer with PSA and MRI. N Engl J Med 2024;391:1083\u201395. https:\/\/doi.org\/10.1056\/NEJMoa2406050.","DOI":"10.1056\/NEJMoa2406050"},{"key":"2026012218562268450_j_biol-2025-1244_ref_004","doi-asserted-by":"crossref","unstructured":"Lewicki, P, Morgan, T. MRI-visible and -invisible prostate cancer. J Urol 2024;212:499\u2013500. https:\/\/doi.org\/10.1097\/ju.0000000000004104.","DOI":"10.1097\/JU.0000000000004104"},{"key":"2026012218562268450_j_biol-2025-1244_ref_005","doi-asserted-by":"crossref","unstructured":"Caglic, I, Sushentsev, N, Syer, T, Lee, KL, Barrett, T. Biparametric MRI in prostate cancer during active surveillance: is it safe? Eur Radiol 2024;34:6217\u201326. https:\/\/doi.org\/10.1007\/s00330-024-10770-z.","DOI":"10.1007\/s00330-024-10770-z"},{"key":"2026012218562268450_j_biol-2025-1244_ref_006","doi-asserted-by":"crossref","unstructured":"Johnson, PM, Chandarana, H. AI-powered diagnostics: transforming prostate cancer diagnosis with MRI. Radiology 2024;312:e241009. https:\/\/doi.org\/10.1148\/radiol.241009.","DOI":"10.1148\/radiol.241009"},{"key":"2026012218562268450_j_biol-2025-1244_ref_007","doi-asserted-by":"crossref","unstructured":"V\u00f6lkel, C, De Wispelaere, N, Weidemann, S, Gorbokon, N, Lennartz, M, Luebke, AM, et al.. Cytokeratin 5 and cytokeratin 6 expressions are unconnected in normal and cancerous tissues and have separate diagnostic implications. Virchows Arch 2022;480:433\u201347. https:\/\/doi.org\/10.1007\/s00428-021-03204-4.","DOI":"10.1007\/s00428-021-03204-4"},{"key":"2026012218562268450_j_biol-2025-1244_ref_008","doi-asserted-by":"crossref","unstructured":"Blessin, NC, Yang, C, Mandelkow, T, Raedler, JB, Li, W, Bady, E, et al.. Automated Ki-67 labeling index assessment in prostate cancer using artificial intelligence and multiplex fluorescence immunohistochemistry. J Pathol 2023;260:5\u201316. https:\/\/doi.org\/10.1002\/path.6057.","DOI":"10.1002\/path.6057"},{"key":"2026012218562268450_j_biol-2025-1244_ref_009","doi-asserted-by":"crossref","unstructured":"Zheng, L, Ling, W, Zhu, D, Li, Z, Li, Y, Zhou, H, et al.. Roquin-1 resolves sepsis-associated acute liver injury by regulating inflammatory profiles via miRNA cargo in extracellular vesicles. iScience 2023;26:107295. https:\/\/doi.org\/10.1016\/j.isci.2023.107295.","DOI":"10.1016\/j.isci.2023.107295"},{"key":"2026012218562268450_j_biol-2025-1244_ref_010","doi-asserted-by":"crossref","unstructured":"Kulac, I, Roudier, MP, Haffner, MC. Molecular pathology of prostate cancer. Clin Lab Med 2024;44:161\u201380. https:\/\/doi.org\/10.1016\/j.cll.2023.08.003.","DOI":"10.1016\/j.cll.2023.08.003"},{"key":"2026012218562268450_j_biol-2025-1244_ref_011","doi-asserted-by":"crossref","unstructured":"Wilson, TK, Zishiri, OT. Prostate cancer: a review of genetics, current biomarkers and personalised treatments. Cancer Rep Hob 2024;7:e70016. https:\/\/doi.org\/10.1002\/cnr2.70016.","DOI":"10.1002\/cnr2.70016"},{"key":"2026012218562268450_j_biol-2025-1244_ref_012","doi-asserted-by":"crossref","unstructured":"Fazekas, T, Shim, SR, Basile, G, Baboudjian, M, K\u00f3i, T, Przydacz, M, et al.. Magnetic resonance imaging in prostate cancer screening: a systematic review and meta-analysis. JAMA Oncol 2024;10:745\u201354. https:\/\/doi.org\/10.1001\/jamaoncol.2024.0734.","DOI":"10.1001\/jamaoncol.2024.0734"},{"key":"2026012218562268450_j_biol-2025-1244_ref_013","doi-asserted-by":"crossref","unstructured":"Yoshizawa, A, Takahara, K, Saruta, M, Zennami, K, Nukaya, T, Fukaya, K, et al.. Combined \u03b1-methylacyl-CoA racemase inhibition and docetaxel treatment reduce cell proliferation and decrease expression of heat shock protein 27 in androgen receptor-variant-7-positive prostate cancer cells. Prostate Int 2021;9:18\u201324. https:\/\/doi.org\/10.1016\/j.prnil.2020.07.001.","DOI":"10.1016\/j.prnil.2020.07.001"},{"key":"2026012218562268450_j_biol-2025-1244_ref_014","doi-asserted-by":"crossref","unstructured":"Fang, AM, Gregg, JR, Pettaway, C, Ma, J, Szklaruk, J, Bathala, TK, et al.. Whole-body MRI for staging prostate cancer: a narrative review. BJU Int 2025;135:13\u201321. https:\/\/doi.org\/10.1111\/bju.16514.","DOI":"10.1111\/bju.16514"},{"key":"2026012218562268450_j_biol-2025-1244_ref_015","doi-asserted-by":"crossref","unstructured":"Iakymenko, OA, Briski, LM, Delma, KS, Jorda, M, Kryvenko, ON. Utility of D2-40, cytokeratin 5\/6, and high-molecular-weight cytokeratin (clone 34\u03b2E12) in distinguishing intraductal spread of urothelial carcinoma from prostatic stromal invasion. Am J Surg Pathol 2022;46:454\u201363. https:\/\/doi.org\/10.1097\/pas.0000000000001816.","DOI":"10.1097\/PAS.0000000000001816"},{"key":"2026012218562268450_j_biol-2025-1244_ref_016","doi-asserted-by":"crossref","unstructured":"Song, Z, Zhou, Q, Zhang, JL, Ouyang, J, Zhang, ZY. Marker Ki-67 is a potential biomarker for the diagnosis and prognosis of prostate cancer based on two cohorts. World J Clin Cases 2024;12:32\u201341. https:\/\/doi.org\/10.12998\/wjcc.v12.i1.32.","DOI":"10.12998\/wjcc.v12.i1.32"},{"key":"2026012218562268450_j_biol-2025-1244_ref_017","doi-asserted-by":"crossref","unstructured":"Wang, Y, Wang, L, Tang, X, Zhang, Y, Zhang, N, Zhi, B, et al.. Development and validation of a nomogram based on biparametric MRI PI-RADS v2.1 and clinical parameters to avoid unnecessary prostate biopsies. BMC Med Imaging 2023;23:106. https:\/\/doi.org\/10.1186\/s12880-023-01074-7.","DOI":"10.1186\/s12880-023-01074-7"},{"key":"2026012218562268450_j_biol-2025-1244_ref_018","doi-asserted-by":"crossref","unstructured":"Cavallo, AU, Stanzione, A, Ponsiglione, A, Trotta, R, Fanni, SC, Ghezzo, S, et al.. Prostate cancer MRI methodological radiomics score: a EuSoMII radiomics auditing group initiative. Eur Radiol 2025;35:1157\u201365. https:\/\/doi.org\/10.1007\/s00330-024-11299-x.","DOI":"10.1007\/s00330-024-11299-x"},{"key":"2026012218562268450_j_biol-2025-1244_ref_019","doi-asserted-by":"crossref","unstructured":"Van der Kwast, TH. Proliferative cribriform prostate cancer: a new opportunity for \u2019promising\u2019 marker KI-67? Histopathology 2023;83:850\u20132. https:\/\/doi.org\/10.1111\/his.15060.","DOI":"10.1111\/his.15060"},{"key":"2026012218562268450_j_biol-2025-1244_ref_020","doi-asserted-by":"crossref","unstructured":"Lima, H, Etchebehere, M, Bogoni, M, Torricelli, C, Nogueira-Lima, E, Deflon, VM, et al.. Theranostics nuclear medicine in prostate cancer. Pharmaceuticals 2024;17:1483. https:\/\/doi.org\/10.3390\/ph17111483.","DOI":"10.3390\/ph17111483"},{"key":"2026012218562268450_j_biol-2025-1244_ref_021","doi-asserted-by":"crossref","unstructured":"Faur, IF, Dobrescu, A, Clim, IA, Pasca, P, Prodan-Barbulescu, C, Tarta, C, et al.. The predictive role of serum lipid levels, p53 and ki-67, according to molecular subtypes in breast cancer: a randomized clinical study. Int J Mol Sci 2024;25:3911. https:\/\/doi.org\/10.3390\/ijms25073911.","DOI":"10.3390\/ijms25073911"},{"key":"2026012218562268450_j_biol-2025-1244_ref_022","doi-asserted-by":"crossref","unstructured":"Jha, N, Phulware, RH, Kumar, A, Singh, A, Durgapal, P, Chowdhury, N, et al.. A study of Ki-67 immunostaining in prostate carcinomas and its correlation with gleason\u2019s score and prognosis: an experience at a tertiary centre in the himalayan foothills. Indian J Surg Oncol 2024;15:341\u20138. https:\/\/doi.org\/10.1007\/s13193-024-01902-4.","DOI":"10.1007\/s13193-024-01902-4"}],"container-title":["Open Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/biol-2025-1244\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/biol-2025-1244\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T18:56:30Z","timestamp":1769108190000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/biol-2025-1244\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,1]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,23]]},"published-print":{"date-parts":[[2026,1,23]]}},"alternative-id":["10.1515\/biol-2025-1244"],"URL":"https:\/\/doi.org\/10.1515\/biol-2025-1244","relation":{},"ISSN":["2391-5412"],"issn-type":[{"value":"2391-5412","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,1]]},"article-number":"20251244"}}